Status:
UNKNOWN
Effect of Brimonidine on Corneal Thickness
Lead Sponsor:
Augenarztpraxis Breisach
Conditions:
Impact of Brimonidine on the Cornea
Eligibility:
All Genders
18+ years
Brief Summary
Brimonidine, an alpha-2 adrenoceptor agonist, is an effective and safe medication which is widely used in glaucoma treatment. Although it is known that it is quickly taken up by the cornea following t...
Eligibility Criteria
Inclusion
- healthy, 18-99 years, normal ophthalmologic history, consent to participate in the study
Exclusion
- any serious medical or neurologic conditions and/or regular use of local or systemic medications
Key Trial Info
Start Date :
December 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2010
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01250236
Start Date
December 1 2010
End Date
December 1 2010
Last Update
December 3 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Augenarztpraxis
Breisach, Baden-Wurttemberg, Germany, 79206